[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562165":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":61,"collaborators":65,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients Treated with single agent, adjuvant anti-PD1 therapy",null,"Patients receiving single agent, adjuvant anti-PD1 therapy (given either as standard of care or as part of a separate investigational study)",[13],"Drug: Single agent, adjuvant anti-PD1 therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Single agent, adjuvant anti-PD1 therapy","One of the following Single-agent, adjuvant anti-PD1 therapies:\n\nNivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.\n\nDose = 240 mg IV every 2 weeks\u002F480 mg every 4 weeks or, Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells.\n\nDose = 200 mg IV every 3 weeks\u002F 400 mg every 6 weeks",[9],[21,22,23,24],"OPDIVO®","Keytruda","Pembrolizumab","Nivolumab",[26],{"name":27,"affiliation":28,"role":29},"John M Kirkwood, MD","UPMC Hillman Cancer Center","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Danielle L Bednarz, RN","CONTACT","(412) 623-1191","bednarzdl@upmc.edu",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Amy Rose, RN","4126478587","kennaj@upmc.edu",[41],{"facility":28,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Pittsburgh","Pennsylvania","15232","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-79.99589,40.44062,{"lat":52,"lon":51},[55,56,57,58],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},{"name":27,"role":29,"phone":10,"phoneExt":10,"email":10},{"name":59,"role":60,"phone":10,"phoneExt":10,"email":10},"Urvashi M Joshi, MD","SUB_INVESTIGATOR",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","John Kirkwood","Professor of Medicine, Immunology, and Dermatology",[66,68],{"name":67,"class":6},"Melanoma Research Foundation",{"name":69,"class":70},"VeyTel Inc.","UNKNOWN","100562165","effects-of-anti-pd1-adjuvant-checkpoint-blockade-immunotherapy-on-atypicaldysplastic-nevi-100562165",false,"NCT06599619","Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical\u002FDysplastic Nevi","A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical\u002FDysplastic Nevi in Patients With Stage IIB-IIIC Melanoma","Inclusion Criteria:\n\n1. Subjects must have at least two atypical nevi of ≥ 4 mm diameter.\n2. Subjects must have a current documented history of melanoma.\n3. Subject must be ≥ 18 years and if female of childbearing potential, must agree to practice effective contraception per institutional SOC if sexually active.\n4. Subjects will have been deemed candidates for adjuvant therapy with single agent anti-PD1 therapy.\n5. Subjects must give written informed consent to participate in this study with consent signed and dated prior to entry into trial.\n\nExclusion Criteria:\n\n1. Patients with non-malignant diseases or indications that would preclude the administration of anti-PD1 therapy such as significant immune suppression or active autoimmune disease requiring disease modifying, immunosuppressive therapy, will be ineligible.\n2. Patients who have previously received anti-PD1 therapy\n3. Patients with history of other active, non-melanoma cancers\n4. Patients who are receiving other anti-neoplastic therapy.","ALL","18 Years",{"count":81,"type":82},30,"ESTIMATED","OBSERVATIONAL","This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical\u002Fdysplastic nevi (A\u002FDN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.",[86],"Melanoma",[88,89,90,91],"anti-PD1 therapy","immune checkpoint blockade","dysplastic nevi","BRAF and NRAS mutations","2026-01-22",{"date":94,"type":95},"2026-01-26","ACTUAL",{"date":97,"type":95},"2025-02-20",{"date":99,"type":82},"2029-05",{"name":63,"class":6},1]